Cagrilintide Powder

What is Cagrilintide?

Cagrilintide Powder is a long-acting amylin analogue that is injected subcutaneously once a week. Canaglitide mimics amylin, a hormone produced by the pancreas and secreted by pancreatic beta cells along with insulin after food intake. It is involved in satiety regulation through activity in the brain and improves glycemic control by delaying gastric emptying and inhibiting glucagon secretion.

Its clinical data shows that it is very effective in humans. On the other hand, calcitonin-based derived peptides are also entering the clinical trial stage. Data from the Science paper show that different peptide drug templates produce distinct binding modes. In the original hypothesis, the molecular structure of the amylin receptor itself would determine how the peptide ligand works. In contrast, in this study, we found significant differences in the conformation and dynamics of the corresponding receptors when bound to different peptides.

Structural comparison of the corresponding receptors activated by calcitonin and amylin. Left: Three subtypes of amylin receptors that bind rAmy; Right: Calcitonin receptors that bind hCT and type I amylin receptors that bind sCT. Amylin forms a unique ‘bypass’ structural motif (black box) in the middle of the peptide chain, thereby inducing an extracellular domain (red box) that is different from the calcitonin-binding structure.

Test Report

 Experiments on Cagrilintide

Obesity is a chronic disease that requires long-term treatment. It increases the risk of type 2 diabetes, hypertension, and cardiovascular disease, or leads to a series of complications, which in turn affects life expectancy and reduces quality of life. For overweight or obese people, lifestyle intervention is the preferred treatment, but some patients still cannot achieve the expected weight loss goals for various reasons and need to lose weight with the help of drugs.

At present, GLP-1 receptor agonists such as liraglutide and semaglutide have been approved by the US FDA for the treatment of specific obese patients. GLP-1 is a hormone secreted by intestinal cells. In addition to stimulating insulin secretion and inhibiting glucagon secretion to promote blood sugar metabolism, it can also delay gastric emptying and suppress appetite.

In addition to the GLP-1 signaling pathway, researchers are also trying to simulate the effects of other hormones related to hunger and satiety. One of them is amylin, a hormone that stimulates satiety. Cagrilintide is the first long-acting amylin analogue studied for weight management. What are its efficacy and safety?

Recently, Professor David C W Lau and his team from the Cumming School of Medicine at the University of Calgary in Canada published a major article in the top medical journal The Lancet, reporting the preliminary efficacy and safety tolerability of cagrilintide in weight management for overweight and obese people.

The results showed that as an adjunct to lifestyle intervention, once-weekly injections of cagrilintide treatment can reduce the average weight by up to 11.5 kg after 26 weeks, and it is safe and tolerable, which is expected to provide a new solution for weight loss treatment.

The study is a multicenter, randomized, double-blind, placebo-controlled and positive-controlled, dose-finding Phase 2 trial conducted in 57 research centers in 10 countries including Canada, Japan, the United Kingdom and the United States. Subjects met the following criteria:

• Age ≥ 18 years, no diabetes;
• Body mass index (BMI) ≥ 30kg/m2; or BMI ≥ 27kg/m2, and hypertension or dyslipidemia.

From March 1 to August 19, 2019, the study included a total of 706 subjects, who were randomly assigned to the drug group or the placebo group in a 6:1 ratio:

• Subcutaneous injection of cagrilintide once a week, divided into 5 dose groups (0.3mg, 0.6mg, 1.2mg, 2.4mg, 4.5mg): 100-102 people in each group;
• Subcutaneous injection of liraglutide 3.0mg once a day: 99 people;
• Dose-matched placebo group: 101 people.

The study lasted for 32 weeks, with a 26-week treatment period (including a 6-week dose escalation period) and a 6-week follow-up period without treatment.
The primary endpoint of the study was the percentage change in body weight from baseline to week 26, and the treatment effect was evaluated for all randomized participants. Safety was evaluated for all participants who received at least one dose of randomized treatment.

Safe and effective for long-term weight management in people with overweight or obesity

Weight change by treatment group: More patients in the cagrilintide 4.5 mg group (purple) lost more than 5%, 10%, and 15% of their body weight compared with liraglutide (red)

• Permanent discontinuation of treatment (n=73 [10%]) occurred at similar rates across treatment groups, primarily due to adverse events (n=30 [4%]). A total of 29 participants (4%) withdrew from the trial.
• Based on trial drug assessments (assuming all participants adhered to treatment throughout the trial), mean percent weight loss was greater for all doses of cagrilintide (0.3 mg-4.5 mg, 6.0%-10.8% [6.4 kg -11.5 kg]) compared with placebo (3.0% [3.3 kg]). Participants in the cagrilintide 4.5 mg group also lost more weight than those in the liraglutide 3.0 mg group (10.8% [11.5 kg] vs 9.0% [9.6 kg]).
• Similar weight loss results were observed based on treatment strategy assessment (regardless of whether participants interrupted or withdrew from treatment).
• In terms of safety, the most common adverse events were gastrointestinal dysfunction (such as nausea, constipation, and diarrhea) and administration site reactions. Compared with the placebo group, the proportion of participants who injected cagrilintide 0.3 mg-4.5 mg experienced gastrointestinal adverse events more frequently (41%–63% vs 32%), mainly nausea (20%-47% vs 18%).

The study showed that cagrilintide treatment can significantly reduce weight and is well tolerated in overweight and obese patients. At the same time, different doses of cagrilintide have significant effects on body weight. The results of this experiment provide a scientific basis for further conducting Phase 3 trials. In the future, in-depth research can be conducted on the effects of higher doses of cagrilintide.

Cagrilintide Powder supplier

Yuantai Organic Bio is committed to providing customers with the highest-quality Cagrilintide Powder 98% and services so that every consumer can enjoy natural, healthy, and high-quality food. If you have any inquiries or needs about our products, please feel free to contact us, and we will reply to you as soon as possible.

Package & Shipment

Our Company and Factory